Clinical Trial Search

Primary: Percentage of Participants With 50% Response Rate Across the 3-month Treatment Period. — 62; 61 percentage of participants — p=0.695

Primary: CSBM1 Success Rate — 9; 8 Participants

Primary: Maternal Anemia at Delivery — 4; 11 Participants — p=0.039

Primary: Visual Analogue Scale — 6.0; 6.8; 5.5; 3.7 units on a scale

Primary: Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24 — -5.9; -2.7 atrophic acne scars — p=< 0.0001

Primary: Change From Baseline in Cutaneous Dermatomyositis at 6 Months — -9 units on a scale — p=< .001

Primary: Area Under the Curve (AUC) Pain Score - Based on Patient-reported Dynamic Numerical Rating Scale (NRS) Pain Scores — 6.39; 4.22 scores on a scale*hour

Primary: Opioid Consumption — 0.41; 1.87 mEQ/kg

Primary: Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Mean MMDs Over Months 4, 5, and 6 in Relation to mPRS — 54.9 percentage of participants…

Primary: AUCtau,Milk — 21.4; 1.59 µg•h/mL, (CV%)

Primary: Reduction in Pain Scores at 60 Minutes — 48.7; 48.3 reduction in visual analog pain score

Primary: Pain as Assessed by the Quality of Recovery (QOR-40) Validated Questionnaire — 30.0; 31.1 score on a scale

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 32; 13; 4; 4 Participants

Primary: Number of Participants With Treatment Emergent AEs and SAEs — 16; 11; 11; 3 Participants

Primary: Absorption of Acetaminophen as Indicated by Area Under the Curve — 3566; 3335 mcg*min/mL